A Phase Ib Study of Ramucirumab plus LY2875358 in Patients with Advanced Cancer

Protocol
14-049
Full Title
A Phase 1b/2 Study of Ramucirumab in Combination with LY2875358 in Patients with Advanced Cancer
Phase
I/II
Purpose

LY2875358 is an investigational drug designed to inhibit cancer growth by blocking the activity of a protein called MET, which some cancer cells need to grow. Ramucirumab is an anticancer drug approved to treat cancer of the stomach and cancer of the junction between the esophagus and the stomach. It inhibits the growth of the blood vessels that tumors need to grow and spread by blocking the activity of a protein called VEGFR2.

In this study, researchers want to find the highest dose of LY2875358 that can be given safely with ramucirumab in patients with advanced solid cancers that are no longer responding to standard treatments. Both drugs are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid cancer which is no longer responding to standard therapies.
  • Patients must have recovered from the serious side effects of previous treatments before entering the study.
  • Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. James J. Harding at 646-888-4314.

Disease(s)
Solid Tumors
Locations